Developing novel oral therapies for neurologic, inflammatory, and metabolic disease.

Reengineering proven biology into safer, orally available therapies.

Our lead program, Ketamir-2, has completed Phase 1 and holds an active IND with the FDA — advancing toward Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN).

  Preclinical Phase 1 Phase 2 Phase 3

Ketamir-2

Chemotherapy-induced peripheral neuropathy (CIPN)
Phase 1 complete

MIRA-55

Chronic inflammatory pain
IND planned

SKNY-1

Obesity and nicotine addiction
Pre-IND
Clinical Preclinical

Improved Therapies with Potential Results

With small changes, MIRA’s technology focuses on big effects that have the potential to redefine therapeutic outcomes, opening up new markets for indications and patients.

Latest Presentation

Latest News

Detailed Stock Information
Mon Jul 6, 2026 09:00 am

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Detailed Stock Information
View Investor Relations

Symbol
NASDAQ: MIRA
Price
$
Volume
Change
{'1d_range' | i8ln tLang}
{scope.data.dayLow | asQHLast tLang}
{scope.data.dayHigh | asQHLast tLang}
{'52weekrange' | i8ln tLang}
{scope.data.week52Low | asQHLast tLang}
{scope.data.week52High | asQHLast tLang}

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.